Fast Track Your Phase 1-11 Vaccine & Cell & Gene Therapy Trials with Avance Clinical

A key advantage for vaccine biotechs is that Avance Clinical is accredited as a gene technology CRO which allows it to manage pre-clinical and clinical trials for vaccines and GMO therapies.

Avance Clinical boasts extensive experience and expertise in conducting Phase II trials specifically tailored to Vaccine and Cell & Gene Therapy products. Our team understands the unique challenges and requirements of these trials, ensuring smooth execution and high-quality results.


Three decades of experience in biotech drug development

Avance Clinical is accredited

In Australia, Avance Clinical is accredited with the Office of the Gene Technology Regulator (OGTR) which has developed globally compliant regulations and accreditations which are in line with international guidelines.

Avance Clinical’s Chief Scientific Officer Dr. Gabriel Kremmidiotis said: “This means that as an OGTR accredited CRO we can support our international biotech clients with extensive OGTR knowledge and experience to accelerate their clinical research. Indeed, we would argue the clarity around the OGTR regulations makes Australia one of the most attractive destinations for Cell and Gene Technology research,” he said.

ClinicReady Success Story

Tetherex Pharmaceuticals

"The Avance team demonstrated flexibility and a solution-oriented attitude in working with us towards obtaining rapid ethics approval, thereby facilitating trial initiation in a timely and efficient manner." - Dr. Russell Rother, President and Chief Operating Officer